News

GPB Scientific Announces Initial Availability of Advanced Cell Separation Platform; Name Change to Curate Biosciences

CARLSBAD, Calif., /PRNewswire/ — GPB Scientific, Inc. has launched its go-to-market activities for the transformational Curate® Cell Processing System to streamline the manufacture of cell therapies, making them economically and reliably available to the largest number of patients. The company’s advanced cell separation platform is in evaluations at select biopharmas, contract manufacturers, and academic centers ahead of the system‘s upcoming commercial introduction. Anticipating the commercial launch, the company is changing its name to “Curate Biosciences” to better communicate its benefits to the gene and cell therapy industry

Cell therapies, typically made from a patient’s own cells, are increasingly important in the fight against cancer and other critical diseases. Curate Biosciences provides a superior cell separation, wash, and concentration solution to deliver more biologically potent results for revolutionary cell therapy treatments. 

The company’s Curate® Cell Processing System is a robust, simple, and automated system that has the potential to enable up to a 50% reduction in the total cost of autologous cell therapy production and a like reduction in the days required to produce a CAR-T dose. The Curate System more than doubles the recovery of patient-derived white blood cells and CD3+ T cell subsets, with exceptional purity in a single-step, closed microfluidic system. 

“Users are now testing the Curate System via our Technology Access Program and observing firsthand its innovative and industry leading ability to produce more high-quality white blood cells for CAR-T oncology cures,” said Mike Grisham, Curate Bioscience’s Chief Executive Officer. “GPB in our prior company name stood for getting people better,’ and this remains our core mission, but the new name reflects our unique capacity to provide more high-quality cells to produce cures for once-intractable diseases.

For more information visit https://www.curatebio.com/

Recent News

07/19/2024

Capra Biosciences Lands $7.5 Million Project Agreement To Demonstrate Platform To Rapidly Scale Pharmaceutical Ingredient Manufacturing

Many ingredients that make up the pharmaceuticals Americans rely on are manufactured overseas. When supply chain issues or shortages occur, as witnessed during the COVID pandemic, it can negatively impact millions of Americans and affect national security. The White House issued an Executive Order in 2022 to stimulate U.S. biomanufacturing. Increasing American biomanufacturing, will provide

07/15/2024

Lupus Treatment with Omega3-Rich Krill Oil Improves Disease Activity

AMPEL BioSolutions, with collaborators Lupus Therapeutics and Aker Biomarine, revealed peer-reviewed results that supplementation with Omega3-rich Krill Oil improves disease activity of autoimmune Lupus patients. Omega3 lipids called polyunsaturated fatty acids (PUFAs) that are found in microscopic shrimp-like crustaceans called Krill from the waters around Antarctica are key to maintaining a low inflammatory state.  Some

07/15/2024

Inorganic Ventures acquires PURE Analytical Laboratories, Combining Unique Capabilities for Precision Manufacturing

Two privately held specialty chemical firms that provide high-purity materials and services for chemical applications, from renewable energy to food and beverages and consumer safety, are combining their capabilities to serve new and expanding precision markets. IV Labs Inc., the parent company of Inorganic Ventures, has acquired PURE Analytical Laboratories, one of the few companies that